Professor
Our laboratory aims at incorporating a systematic approach to bioanalysis, preclinical and clinical research guided by standard operating procedures and good clinical and laboratory practices so as to achieve the highest level of efficiency, accuracy and reproducibility in our pursuit of excellence in clinical pharmacology and experimental therapeutics (bedside-to-bench pharmacology). We aim to become a centre of excellence for research, training and services in clinical pharmacology and experimental therapeutics encompassing a range of activities including but not limited to drug development, personalized medicine, pharmacovigilance and pharmacoeconomics.
Phase 1 unit: The department has an active phase-1 unit to foster pharmacokinetic, pharmacogenetic, BA/BE and first-in-human clinical trials. The 2 bedded ward is a specialized unit capable of providing round the clock care and supervision to the study participants under the stewardship of an excellent team of study investigators, medical oncology and nursing staff.
Bioanalytical unit: The department has a dedicated bioanalytical unit with high resolution Q Trap LC-MS/MS systems, UPLC RS-3000 Model Dionex and HPLC JASCO with absorbance, fluorescence detector. The division is led by a technical team with a vast experience in development, validation and analysis of preclinical and clinical biological matrices. They also form an integral part of ongoing therapeutic drug monitoring services, toxicokinetic, metabolic profiling and BA/BE clinical trials in the department.
Preclinical research: The department is actively involved in developing therapeutic interventions for various cancers as well as the mitigation of serious adverse effects associated with cancer treatment. This includes development of radioprotectors and drugs for the prevention of morbidities associated with bone marrow transplantation such as graft versus host disease (GvHD). The pharmacokinetics and efficacy of drugs in special situations such as malnutrition are also being investigated. The lab undertakes end-to-end non-clinical investigations including pharmacokinetics and biodistribution, toxicity, efficacy and mechanistic studies.
The overall objective of this proposal is to study the pharmacogenetics - pharmacokinetics correlation (PG-PK) o… more
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an important treatment modality for leukaemia.… more
Asparaginase is central to the treatment of acute lymphoblastic leukemia. However, due to bacterial origin EcA (… more
Anticancer drugs like 6-mercaptopurine and 13-cis-retinoic acid are integral components of the treatment regimen… more
Nutritional status is one of the factors that cause inter-patient variability in response to anti-cancer drugs.… more
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and contributes 85% of all lung cancer… more
Cancer risks associated with the use of smokeless tobacco (SLT) products worldwide vary drastically. There is a… more
We are currently focusing on developing new strategies to make allogeneic Bone Marrow Transplantation (BMT) safe… more
Scientific Officer 'D'
Scientific Officer 'D'
Scientific Officer 'F'
Scientific Officer 'F'
Sharma, J. B., Krishnamurthy, M. N., Awase, A., Joshi, A., Patil, V., Noronha, V., Prabhash, K., & Gota, V.
Otitoju, A. P., Longdet, I. Y., Alemika, T. E., & Gota, V. P.
Gota, V., Nookala, M., Bonda, A., Karanam, A., Shriyan, B., Kembhavi, Y., Gurjar, M., Patil, A., Singh, A., Goyal, N., & Gupta, S.
Hole, A., Tyagi, G., Deshmukh, A., Deshpande, R., Gota, V., Chaturvedi, P., & Krishna, C. M.